在阿尔茨海默病的血生物标志物和认知功能之间白质强度的阶段依赖调解
Hui Juan Chen1, Yihao Guo1, Weiyuan Huang1
1Department of Radiology, Hainan General Hospital, and Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.
Translational psychiatry
|March 3, 2026
概括
在阿尔茨海默病 (AD) 中,白质过强度 (WMH) 显示了认知衰退的阶段依赖调解. 早期阶段通过WMH将粉样蛋白与认知联系起来,而后期阶段涉及神经炎症和神经退行.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 生物标志物 生物标志物
背景情况:
- 白质超强度 (WMHs) 在阿尔茨海默病 (AD) 中很普遍,并与认知障碍有关.
- 区域性WMH体积及其与认知领域和血生物标志物的关联在AD进展中的特定作用尚未完全理解.
研究的目的:
- 调查区域WMH体积,认知功能和阿尔茨海默氏病频谱内的血生物标志物之间的关系.
- 探索WMH在不同疾病阶段从生物标志物到认知衰退的途径中的调解效应.
主要方法:
- 311名参与者 (健康对照组,主观认知衰退,轻度认知障碍,AD) 接受了神经心理测试,MRI和血生物标记分析.
- 根据位置 (右心室,周心室,皮层,深层) 划分和分类WMH体积.
- 进行了相关性,路径分析和引导调解分析.
主要成果:
- 与其他组相比,AD组表现出明显增加的柔心性WMH (juxWMH) 容量.
- 在AD组中观察到显著更大的周周结膜WMH (pWMH) 和下皮层WMH (jcWMH) 卷.
- 较低的血Aβ42 / Aβ40比率与较高的juxWMH,pWMH和jcWMH体积相关. 较高的juxWMH量与更差的记忆,语言和执行功能有关.
- 调解分析显示,在没有受损的个体中,juxWMH和pWMH调解的粉样蛋白-认知关联.
- 在受损个体中,WMH调解涉及粉样蛋白,神经炎症和神经退行途径.
结论:
- 特定位置的WMH体积与阿尔茨海默病的认知衰退和血生物标志物有关.
- 在AD病理生理学中,WMH表现出阶段依赖的调解模式,从粉样蛋白中心演变为多因素过程.
- 这些发现凸显了WMH作为AD不同阶段的治疗点的潜力.
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35